Targeted Therapy & Precision Oncology
Part of Healthcare - Oncology
 LLY | Eli Lilly & Co. | $1.0t | $1190.00 | -3.5% | 2.6M |
 RVMD | Revolution Medicines, Inc. Common Stock | $38.8b | $217.31 | +1.8% | 3.3M |
 INCY | Incyte Genomics Inc | $24.2b | $129.78 | -1.2% | 540.3K |
 JAZZ | Jazz Pharmaceuticals, Inc. | $15.9b | $249.61 | -4.2% | 2.2M |
 EXEL | Exelixis Inc | $13.3b | $56.65 | -1.1% | 1.4M |
 CORT | Corcept Therapeutics Inc. | $12.4b | $120.68 | -3.0% | 653.6K |
 HALO | Halozyme Therapeutics, Inc. | $9.8b | $107.09 | -2.1% | 1.2M |
 NUVL | Nuvalent, Inc. Class A Common Stock | $9.8b | $123.96 | 0.0% | N/A |
 COGT | Cogent Biosciences, Inc. Common Stock | $6.7b | $37.10 | -0.2% | 894.5K |
 ERAS | Erasca, Inc. Common Stock | $6.3b | $18.95 | +7.9% | 6.9M |
 TNGX | Tango Therapeutics, Inc. | $4.4b | $26.04 | +2.9% | 2.9M |
 CELC | Celcuity Inc. Common Stock | $4.2b | $94.92 | +3.1% | 570.4K |
 RLAY | Relay Therapeutics, Inc. Common Stock | $4.1b | $19.66 | -5.4% | 2.6M |
 ELVN | Enliven Therapeutics, Inc. Common Stock | $3.8b | $60.78 | -0.2% | 798.9K |
 IDYA | IDEAYA Biosciences, Inc. Common Stock | $3.4b | $41.58 | -2.1% | 609.1K |
 IMNM | Immunome, Inc. | $2.6b | $28.43 | -2.1% | 443.3K |
 NRIX | Nurix Therapeutics, Inc. Common stock | $2.4b | $26.70 | -0.9% | 441.0K |
 DAWN | Day One Biopharmaceuticals, Inc. Common Stock | $2.2b | $21.52 | -0.0% | 3.0M |
 NUVB | Nuvation Bio Inc. | $2.1b | $6.95 | -2.0% | 2.9M |
 BHVN | Biohaven Ltd. | $2.0b | $16.94 | +18.8% | 14.8M |
 TYRA | Tyra Biosciences, Inc. Common Stock | $1.9b | $26.50 | -1.7% | 221.6K |
 URGN | UroGen Pharma Ltd. Ordinary Shares | $1.9b | $47.56 | -1.0% | 554.6K |
 DMRA | Damora Therapeutics, Inc. Ordinary Shares | $1.8b | $30.37 | -0.7% | 151.0K |
 NVCR | NovoCure Limited Ordinary Shares | $1.8b | $17.89 | +1.7% | 668.8K |
 ZYME | Zymeworks Inc. | $1.6b | $29.49 | +6.7% | 1.1M |
 VIR | Vir Biotechnology, Inc. Common Stock | $1.5b | $10.90 | +3.6% | 1.9M |
 GLUE | Monte Rosa Therapeutics, Inc. Common Stock | $1.4b | $14.38 | -1.2% | 844.9K |
 AVBP | ArriVent BioPharma, Inc. Common Stock | $1.4b | $31.20 | -0.6% | 326.3K |
 ORIC | Oric Pharmaceuticals, Inc. Common Stock | $1.1b | $13.90 | +0.5% | 952.2K |
 OLMA | Olema Pharmaceuticals, Inc. Common Stock | $1.0b | $10.77 | -0.6% | 388.0K |
 GERN | Geron Corp | $0.8b | $1.54 | -0.6% | 8.4M |
 KURA | Kura Oncology, Inc. | $0.8b | $13.28 | -3.9% | 2.3M |
 MNPR | Monopar Therapeutics Inc. Common Stock | $0.7b | $113.28 | +2.6% | 117.7K |
 RIGL | Rigel Pharmaceuticals Inc. (New) | $0.7b | $46.10 | -0.6% | 202.2K |
 NVCT | Nuvectis Pharma, Inc. Common Stock | $0.7b | $24.83 | -3.6% | 332.4K |
 BBOT | BridgeBio Oncology Therapeutics, Inc. Common Stock | $0.6b | $9.20 | -1.3% | 181.0K |
 RLMD | Relmada Therapeutics, Inc. Common Stock | $0.6b | $4.55 | -1.1% | 411.9K |
 ARVN | Arvinas, Inc | $0.5b | $9.56 | -2.9% | 447.8K |
 VSTM | Verastem, Inc. | $0.5b | $7.29 | +4.4% | 1.5M |
 DCTH | Delcath Systems Inc | $421.9m | $16.99 | -3.0% | 314.1K |
 STRO | Sutro Biopharma, Inc. | $415.9m | $21.39 | -0.4% | 200.5K |
 PBYI | PUMA BIOTECHNOLOGY INC | $391.4m | $9.16 | -1.7% | 305.3K |
 CCCC | C4 Therapeutics, Inc. | $384.8m | $4.17 | +0.7% | 1.6M |
 PRLD | Prelude Therapeutics Incorporated | $349.6m | $6.63 | -0.4% | 443.1K |
 ZNTL | Zentalis Pharmaceuticals, Inc. Common Stock | $331.0m | $3.89 | 0.0% | 528.8K |
 TLSI | TriSalus Life Sciences, Inc. Common Stock | $291.7m | $4.93 | -1.9% | 73.8K |
 IMRX | Immuneering Corporation Class A Common Stock | $267.2m | $5.20 | -1.5% | 416.7K |
 WHWK | Whitehawk Therapeutics, Inc. Common Stock | $195.8m | $4.98 | -4.9% | 114.8K |
 PYXS | Pyxis Oncology, Inc. Common Stock | $192.6m | $3.34 | +8.8% | 604.1K |
 CRBP | Corbus Pharmaceuticals Holdings, Inc. | $166.2m | $11.34 | -0.3% | 366.3K |